Monmouth Junction, NJ, September 27, 2011 — MicroDose Therapeutx, Inc. today announced that the first human subject has been dosed in a Phase 1 clinical trial of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).  This Phase 1 trial follows the reactivation of the United States IND for MDT-637 as re-formulated for delivery using MicroDose’s proprietary dry powder nebulizer.

The Phase 1 clinical trial is a U.S.-based, single ascending dose, randomized, placebo controlled trial studying the safety, tolerability and pharmacokinetics of MDT-637 in 48 healthy adult subjects.

MDT-637 is a fusion inhibitor that has been shown to block RSV infection in preclinical testing.  The product is formulated for inhaled delivery via MicroDose’s proprietary dry powder nebulizer, a novel device which allows for the rapid delivery of dry powder medications via tidal inhalation to the site of infection in the respiratory tract.

“We are pleased to announce first subject dosing as we initiate clinical testing for MDT-637,” said Robert Cook, Ph.D., Senior Director, Product Commercialization Group, at MicroDose.  “This study will provide important safety and pharmacokinetic data for assisting dose selection in subsequent clinical development.”

MicroDose is developing MDT-637 in collaboration with Gilead Sciences, Inc. under an agreement announced April 20, 2011. As previously reported, MicroDose is responsible for the development of MDT-637 through Phase IIa clinical trials.

- more -

About RSV

RSV is a pathogen that infects the human respiratory tract, potentially leading to infections such as bronchiolitis and pneumonia.  While most otherwise healthy people recover from the virus within a few weeks, the Centers for Disease Control and Prevention (CDC) estimates that up to 125,000 infants are hospitalized due to RSV infection in the United States each year.  There is an increased

risk of severe disease in premature infants, the immune-compromised, individuals with chronic obstructive pulmonary disease (COPD) and asthma, and the elderly.  Globally, the annual death rate from RSV is estimated at more than 160,000 and the clinical burden of RSV infection is comparable to that of influenza.

About MicroDose Therapeutx

MicroDose Therapeutx is a private pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on pulmonary and oral drug delivery platforms.  The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies.  MicroDose’s current pipeline targets respiratory diseases such as asthma, COPD and RSV, as well as IBS-C and constipation.

#  #  #

For more information on MicroDose Therapeutx, please visit www.mdtx.com

MONMOUTH JUNCTION, N.J., (BUSINESS WIRE) May 2, 2011 – MicroDose Therapeutx, Inc. (MicroDose) today announced that a development  milestone in its collaboration with Novartis  has been achieved, triggering a payment under the multi-product development and licensing agreement for the MicroDose proprietary dry powder inhaler (DPI). This milestone signals the successful incorporation of MicroDose’s DPI technology into a Novartis platform pulmonary device.

As previously announced, under the terms of the agreement Novartis is funding development and commercialization of products that employ MicroDose’s DPI technology for the administration of Novartis’ proprietary respiratory compounds. In addition to the upfront payment received, MicroDose is eligible for additional milestone payments and royalties on product sales.

“MicroDose is pleased to announce the achievement of this milestone” commented David Byron, Vice President of Research and Development, MicroDose. “The collaboration with Novartis has yielded a platform embodiment of MicroDose’s DPI technology for Novartis to use in advancing development of a number of their proprietary respiratory pipeline products”

About the MicroDose DPI
The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose.  By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance versus other inhalers, for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture.  MicroDose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Therapeutx
MicroDose Therapeutx is a private pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on pulmonary and oral drug delivery platforms.  The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies.  MicroDose’s current pipeline targets respiratory diseases such as asthma, COPD and respiratory syncytial virus (RSV), as well as IBS-C and constipation.  More can be found at our website; www.mdtx.com.

Contacts:

For MicroDose Therapeutx:
Scott Fleming, Sr. Vice President, Sales & Marketing
Tel: (732) 355-2114  E: sfleming@mdtx.com

GILEAD AND MICRODOSE THERAPEUTX ANNOUNCE LICENSE AND COLLABORATION AGREEMENT TO DEVELOP MDT-637 FOR TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS

Foster City, CA and Monmouth Junction, NJ, April 20, 2011 — Gilead Sciences, Inc.
(Nasdaq: GILD) and MicroDose Therapeutx, Inc. today announced that the companies have entered into an exclusive worldwide license and collaboration agreement for the development and commercialization of MDT-637, MicroDose’s inhalable small molecule antiviral fusion inhibitor for the treatment of respiratory syncytial virus (RSV).

Under the terms of the agreement, Gilead will pay MicroDose an upfront payment and provide research funding to support MicroDose’s continued development of MDT-637 through Phase IIa clinical trials.  Gilead can assume full responsibility for clinical development following Phase IIa.  MicroDose also could receive additional payments based upon the achievement of certain development, regulatory and commercial milestones, as well as development fees and royalties on future potential net sales.

MDT-637 is a fusion inhibitor that has been shown to block RSV infection in preclinical testing.  The product is formulated for pulmonary delivery via MicroDose’s proprietary dry powder inhaler, which allows for rapid delivery to the site of infection (in the respiratory tract).  MicroDose plans to file the Investigational New Drug (IND) reactivation with the U.S. Food and Drug Administration (FDA) and to initiate a Phase I study this year with MDT-637.

“This strategic collaboration is a significant milestone in MicroDose’s vision to develop first-in-class therapies for major unmet medical needs,” said Anand Gumaste, President and CEO of MicroDose.  “Given Gilead’s scientific and clinical expertise in virology, this partnership provides a strong validation of the potential for MDT-637 to become an important therapeutic advance for those affected by RSV infection.”

“There is an urgent need to improve upon RSV treatment and care,” said Norbert W. Bischofberger, PhD, Gilead’s Executive Vice President, Research and Development and Chief Scientific Officer.  “We believe this program aligns well with our expertise in both antiviral and respiratory drug development and we look forward to working with the MicroDose team to advance MDT-637 into clinical testing.”

About RSV

RSV is a pathogen that infects the human respiratory tract, potentially leading to infections such as bronchiolitis and pneumonia.  While most otherwise healthy people recover from the virus within a few weeks, the Centers for Disease Control and Prevention (CDC) estimates that up to 125,000 infants are hospitalized due to RSV infection in the United States each year.  There is an increased

risk of severe disease in premature infants, the immune-compromised, individuals with chronic obstructive pulmonary disease (COPD) and asthma, and the elderly.  Globally, the annual death rate from RSV is estimated at more than 160,000 and the clinical burden of RSV infection is comparable to that of influenza.

About MicroDose Therapeutx

MicroDose Therapeutx is a private pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on pulmonary and oral drug delivery platforms.  The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies.  MicroDose’s current pipeline targets respiratory diseases such as asthma, COPD and RSV, as well as IBS-C and constipation. For more information, visit www.mdtx.com.

About Gilead Sciences

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need.  The company’s mission is to advance the care of patients suffering from life-threatening diseases worldwide.  Headquartered in Foster City, California, Gilead has operations in North America, Europe and Asia Pacific.

Gilead Forward-Looking Statement

This press release includes forward-looking statements, within the meaning of the Private Securities Litigation Reform Act of 1995, that are subject to risks, uncertainties and other factors, including risks related to the development of MDT-637 for RSV infection and MicroDose’s ability to file the IND reactivation and initiate a Phase I study with MDT-637 as currently contemplated.  Further, there are risks related to MicoDose’s ability to enroll patients in such a study, the possibility of unfavorable results of the study, the need to modify or delay the study or to perform additional trials and the risk of failing to obtain approvals from the regulatory authorities. As a result, MDT-637 may never be successfully commercialized.  In addition, Gilead and MicroDose may make a strategic decision to discontinue development of MDT-637.  These risks, uncertainties and other factors could cause actual results to differ materially from those referred to in the forward-looking statements.  The reader is cautioned not to rely on these forward-looking statements.  These and other risks are described in detail in Gilead’s Annual Report on Form 10-K for the year ended December 31, 2010, as filed with the U.S. Securities and Exchange Commission.  All forward-looking statements are based on information currently available to Gilead, and Gilead assumes no obligation to update any such forward-looking statements.

#  #  #

For more information on Gilead Sciences, please visit www.gilead.com or call the Gilead Public Affairs Department at 1-800-GILEAD-5 (1-800-445-3235).

Non-dilutive grants support development programs in RSV disease, COPD and IBS-C

MONMOUTH JUNCTION, N.J. USA—November 4, 2010—MicroDose Therapeutx Inc. today announced that it was awarded Therapeutic Discovery Project grants, totaling $977,917, by the U.S. Internal Revenue Service (IRS) in support of four major programs the company is currently progressing.

The grants, which target therapeutic discovery projects that show a reasonable potential to result in new therapies to treat areas of unmet medical need or prevent or treat chronic or acute diseases, among other criteria, were awarded to MicroDose to support four internal projects, two of which are highlighted below:

• MDT-637 – Treatment of Respiratory Syncytial Virus (RSV)
• MDT-006 – Treatment of Gastrointestinal Diseases

Commenting on the award, John Krall, Sr. Director of Finance at MicroDose said, ““We are poised to make a significant impact in these important therapeutic areas.  Being selected against steep odds to receive these grants is an honor for our Company, and the funds will enable MicroDose to move at a more rapid pace toward achieving our goals.”

This award comes on the heels of MicroDose being selected by NJBIZ as one of New Jersey’s 2010 Fifty Fastest Growing companies, an award MicroDose will receive on November 15^th.

About MDT-637 and RSV disease

RSV (respiratory syncytial virus) is a highly contagious virus that infects over 90% of children worldwide during the first two years of life and for which there are currently no vaccines nor any effective treatments available.  RSV causes considerable morbidity and mortality in infants, the immuno-compromised, the elderly, and those with asthma and COPD, and in 2009 the New England Journal of Medicine deemed ‘its control a worldwide priority’.  MDT-637 is a clinical stage, anti-viral product that has been shown to effectively block RSV infection both in vitro and in animal models for RSV infection.  MDT-637 acts by targeting the viral fusion protein, which is the only validated target for RSV treatments. The compound is inhaled, which allows for rapid delivery to the site of virus infection, and has been shown to be safe and well tolerated in multiple human safety trials.  MicroDose is developing MDT-637 as a dry powder for inhalation via its novel dry powder inhaler (DPI).

About MDT-006, constipation and IBS-C (irritable bowel syndrome with constipation)

Irritable Bowel Syndrome and constipation afflict an estimated 20 to 50 million US adults and according to Datamonitor, is one of the top 10 reasons for visits to primary care physicians. MDT-006 is a novel, highly selective, non absorbed, small molecule. MDT-006 works by activating of the P2Y2 receptor which stimulates chloride ion secretion into the gastrointestinal tract, a clinically validated mechanism to increase fluid secretion and accelerate gastrointestinal motility. MDT-006 may represent a novel and effective treatment for patients suffering from chronic constipation and IBS-C and in addition has demonstrated application in the treatment of cystic fibrosis and dry eye syndrome.

About MicroDose Therapeutx
MicroDose Therapeutx is a privately-held specialty pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases.  The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral, and transdermal delivery of medications.  The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies.  More can be found at our website; www.mdtx.com.

Contact: Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com

Judith Fleischer, Ex Machina D x M, 908-469-0554 or jfleischer@exmachinadxm.com

MONMOUTH JUNCTION, N.J. USA – March 3, 2010 — MicroDose Therapeutx Inc. today announced that it has been invited to give a corporate presentation at Cowen & Company, LLC’s 30th Annual Healthcare Conference being held at the Boston Marriot Copley Place, Boston, MA from Monday March 8th through Thursday, March 11th, 2010.

Anand V. Gumaste, PhD, MicroDose’s President and Chief Executive Officer, will provide an overview of the company on Tuesday, March 9th at 10:00a.m. Eastern Standard Time.

About MicroDose Therapeutx

MicroDose Therapeutx is a privately-held specialty pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral and transdermal delivery of medications. The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies. MicroDose’s products and platforms currently target respiratory disease states such as asthma, COPD and RSV disease, as well as constipation and diabetes among others.

For more information on MicroDose Therapeutx, please visit www.mdtx.com or contact:

Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com

Acquisition expands MicroDose’s portfolio in its PolyCap® oral delivery platform

MONMOUTH JUNCTION, N.J. USA – December 1, 2009 — MicroDose Therapeutx Inc. today announced that it has acquired a portfolio of compounds for the potential treatment of chronic constipation, irritable bowel syndrome with constipation (IBS-C) and other diseases, from Epix Pharmaceuticals, Inc. (EPIX) (Lexington, MA). The lead compound in the portfolio, formerly known as EPX-16006, is a novel, highly selective, oral, small molecule, now called MDT-006. The compound is extremely potent, possibly allowing for once-a-day dosing, and has demonstrated efficacy and safety in preclinical studies. Because of MDT-006’s unique mechanism of action, it may also have application in non-gastrointestinal diseases. MicroDose intends to develop MDT-006 initially in an oral format using its PolyCap® delivery platform.

Commenting on the product acquisition, Mike Martin, Vice President, Licensing and Business Development at MicroDose said “Current pharmaceutical options are extremely limited to treat chronic constipation resulting from IBS and there is a substantial commercial opportunity for a safe and effective therapy. MDT-006 offers an attractive approach to current therapy and because the compound acts primarily on the colon and is not absorbed, it is expected to have fewer gastrointestinal and systemic side effects.”

MicroDose acquired EPIX’s global rights to the compounds in an outright purchase for cash. The acquisition includes rights to EPX 16006, its chemical analogues and supporting patents and development data, including toxicology studies and related materials. MicroDose plans to further develop MDT-006 internally and to seek partnering opportunities at an appropriate future stage of the development program.

The EPIX transaction is the second portfolio acquisition by MicroDose in the last two months. MicroDose earlier announced its purchase from ViroPharma Incorporated of anti-viral investigational compounds (MDT-637) for the potential prevention and treatment of respiratory syncytial virus or RSV disease.

About IBS disease

While the exact cause of Irritable Bowel Syndrome is unknown, it is estimated that between 20 and 40 million US adults suffer from this disease. While both genders are candidates for IBS there is a higher incidence among women. According to Datamonitor, “IBS is one of the most common functional disorders and is one of the top 10 reasons for visits to primary care physicians.” Symptoms of the disease include constipation, abdominal pain, bloating, and fatigue. IBS is often prevalent among patients suffering from psychiatric disorders such as depression and anxiety.

About MDT-006

MDT-006 is a novel, highly selective, non absorbed, small molecule. In pre-clinical animal studies, the compound increased feces production and water content, reduced gastrointestinal transit time and further had no detectable plasma levels. MDT-006 has many potential uses, including as a treatment for chronic constipation and constipation related to IBS (IBS-C) and to side effects associated with medications and surgical procedures. It may also have applications for respiratory and ocular indications.

About PolyCap®

MicroDose’s patented PolyCap® system is a proprietary approach that enables the rapid development of fixed-dose-combination therapies in a single capsule, but separated by a physical barrier. This innovative approach relies on the proven strengths of capsules and the advantages of a barrier system, allowing for more rapid product development timelines, reduced development risk, and lower regulatory requirements.

About MicroDose Therapeutx

MicroDose Therapeutx is a privately-held specialty pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases. The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral and transdermal delivery of medications. The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies. MicroDose’s products and platforms currently target respiratory disease states such as asthma, COPD and RSV disease, as well as diabetes, hypertension and hyperlipidemia. For more about MicroDose, see our website at www.mdtx.com.

Contact: Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com

Judith Fleischer, Ex Machina D x M, 908-469-0554 or jfleischer@exmachinadxm.com

MicroDose Therapeutx Acquires ViroPharma Portfolio of Investigational Compounds for Treatment of Respiratory Syncytial Virus (RSV)

Acquisition expands MicroDose’s portfolio of proprietary products.

MONMOUTH JUNCTION, N.J. USA—November 9, 2009—MicroDose Therapeutx Inc. (formerly MicroDose Technologies) today announced that it has acquired a portfolio of compounds for the potential treatment of respiratory syncytial virus (RSV) from ViroPharma Incorporated (Exton, PA).  The lead investigational compound in the portfolio is an inhalable small molecule fusion inhibitor, now called MDT-637.  This highly potent compound has demonstrated antiviral activity in preclinical studies in both prophylaxis and treatment, and was generally well tolerated in multiple adult volunteer Phase I studies.  MicroDose plans to develop the newly acquired compound in dry powder format for inhalation via MicroDose’s novel dry powder inhaler (DPI).

RSV is a highly contagious virus that is a major health threat to several high-risk populations and, with no effective treatments presently available, represents a major unmet medical need. RSV infects over 90% of children worldwide during the first two years of life and causes considerable morbidity and mortality in premature infants, the immuno-compromised, the elderly, and individuals with asthma and chronic obstructive pulmonary disease (COPD).

Commenting on the acquisition, Anand Gumaste, President & CEO of MicroDose said, “Earlier this year we announced that we would be expanding our mission by developing proprietary products that address large market opportunities and are enabled by our game-changing drug delivery technologies.  The acquisition of ViroPharma’s portfolio is a perfect fit with this strategy, as it leverages our next generation inhaler platform as well as our experience in respiratory product development to address a large unmet need in RSV disease.”

“The unique capabilities of the MicroDose inhaler are ideal for the delivery of MDT-637 as it can realize the molecule’s broadest potential across the range of populations from pediatric to the elderly, groups not well served by today’s DPIs.  The potential for both treatment and prevention across this spectrum of patients, combined with non-invasive inhaled delivery to the site of infection, could greatly expand this market,” explains Scott Fleming, MicroDose’s Sr. Vice President, Sales & Marketing.

About RSV disease

RSV is a pathogen that attacks the human respiratory tract.  There are currently no treatment options approved in the U.S. for this virus among the infant, pediatric, and adult populations that are susceptible to it.  The February 2009 edition of the New England Journal of Medicine stated that “RSV is associated with substantial morbidity in US children in both the inpatient and outpatient settings and….. its control is a worldwide priority.”  Globally, the annual death rate from RSV is estimated at 160,000 and the clinical burden of RSV infection is comparable to that of influenza.  The market opportunity for treatments addressing RSV is significant and growing.  MedImmune’s monoclonal antibody, Synagis^®, an intramuscular injection approved only for prophylactic use against RSV in premature infants, has annual worldwide sales in excess of $1 billion.

About MDT-637

MDT-637 is a clinical stage product that has been shown to effectively block RSV infection both in vitro and in the cotton rat, which is the accepted animal model for RSV infection.  MDT-637 acts by targeting the viral fusion protein, which is the only validated target for RSV treatments. The compound is inhaled, which allows for rapid delivery to the site of virus infection, the lungs, and has been shown to be safe and well tolerated in multiple human safety trials.  Results from animal studies indicate that MDT-637 could find use as both a preventative and a treatment of RSV infection.  MDT-637 will be formulated for pulmonary delivery via MicroDose’s proprietary dry powder inhaler.

About MicroDose Therapeutx

MicroDose Therapeutx is a privately-held specialty pharmaceutical company dedicated to improving the quality of life for people suffering from serious diseases.  The company focuses on developing proprietary products that address large unmet market opportunities, and on drug delivery platforms for the pulmonary, oral, and transdermal delivery of medications.  The company develops its products and technologies independently, as well as in partnership with leading pharmaceutical companies.  MicroDose’s products and platforms currently target respiratory disease states such as asthma, chronic obstructive pulmonary disease (COPD), and respiratory syncytial virus (RSV), as well as diabetes, hypertension, and hyperlipidemia. More can be found at our website; www.mdtx.com.

Contact: Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com

Judith Fleischer, Ex Machina D x M, 908-469-0554 or jfleischer@exmachinadxm.com

Monmouth Junction, NJ, USA—April 27, 2009— MicroDose Technologies, a leader in next generation drug delivery technologies, is now MicroDose Therapeutx (MDT). Founded in 1998 with the introduction of its revolutionary electronic dry powder inhaler among other technologies, privately held MicroDose Therapeutx focuses on the creation of products utilizing its proprietary drug delivery technologies.

The MDT name change reflects the expansion of its business, its capabilities and its products. The company plans to expand its portfolio from primarily third party products incorporating its technologies to one that includes internally developed specialty pharmaceutical products. Utilizing its game changing drug delivery technologies, MicroDose Therapeutx plans to create easy to use therapies with improved performance, safety and efficacy. In addition to its new name, MDT has launched a new web site, www.mdtx.com.

MDT’s focus in pulmonary delivery is on inhalation therapies for respiratory diseases like asthma and COPD, and supportive care for respiratory illnesses, such as pulmonary infections. Other priority areas include treatments for pain, diabetes and pulmonary hypertension, where pulmonary delivery can enhance efficacy. For oral dosage products utilizing our PolyCap® system, we will focus on products that enhance treatment effectiveness in patients suffering from major diseases like diabetes, hypertension, and hyperlipidemia.

Describing the new vision for the company, Anand Gumaste, President and Chief Executive Officer, states, “The name change reflects our decision to expand the company’s business model from a strictly technology out-licensing model to one where the company would also carry certain pharmaceutical products through proof-of-concept before out-licensing or seeking partners for further development. This expansion of our business strategy will give us a greater degree of control over the company’s growth.”

About MicroDose Therapeutx

MicroDose Therapeutx (MDT), formerly MicroDose Technologies, is dedicated to improving the quality of life for people suffering from serious diseases by creating improved pharmaceutical products. The company is a leader in the application of proprietary drug delivery technologies; developing advanced pulmonary, combination oral dosage; and other technologies and products for the pharmaceutical and biotechnology industries.

MicroDose’s partners and programs include: multi-product licensing and development agreements with Novartis and Merck & Co., Inc., the joint development of an inhaled insulin product, and an inhaler for the delivery of a nerve agent antidote for the US Department of Defense.

Contact: Scott Fleming, Senior V.P., Sales & Marketing at 732-355-2114 or sfleming@mdtx.com

As previously announced, Merck will fund development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds. In addition to the upfront payment received upon commencement of the collaboration, MicroDose is eligible for additional milestone payments on this product and for the development of other products and royalties on revenues from all products developed under the license.

“MicroDose is proud to announce the start of the study by Merck which, in fact, represents the second human clinical study to be initiated under a U.S. Investigational New Drug application using our inhaler technology in the last 18 months” commented David Byron, Vice President of Research and Development, MicroDose. “Achieving this milestone with Merck so quickly is a strong indicator of the excellent working relationship that underpins this collaboration.”

About the MicroDose DPI The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture, features MicroDose hopes will be confirmed through clinical trials. MicroDose believes that the flexibility of the
inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Technologies

MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries. In addition to the collaboration with Merck, MicroDose’s other partnerships include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the U.S. Department of Defense, in collaboration with the University of Pittsburgh.

MicroDose has ongoing feasibility programs with other major pharmaceutical companies and is also conducting internal development programs for products employing its inhaler technology, and for combination oral dosage products employing its PolyCap(TM) technology, in the areas of diabetes, hypertension and hyperlipidemia.

For more information visit us at http://www.microdose-tech.com
SOURCE MicroDose Technologies, Inc

Under the terms of the agreement, Merck will fund development and commercialization of products that employ MicroDose’s DPI technology for the administration of Merck compounds. MicroDose will receive an upfront payment and will be eligible for milestone payments totaling $32 million for successful development of the first product as well as royalties on product revenues. Additional products will also be eligible for milestones and royalties.

“We are delighted to expand our relationship with Merck, who have already proved to be very collaborative and decisive in their actions,” commented Scott Fleming, Senior Vice President, Marketing of MicroDose. “This agreement to bring innovative inhalation products to market is a positive milestone in the continued growth of MicroDose and represents further validation of our DPI technology.”

“Through this agreement Merck has gained access to a novel delivery technology that has the potential to facilitate the
administration of and ensure patient compliance with drug treatments targeting the lungs,” said Soren Bo Christiansen, General Manager Bone, Respiratory, Immunology and Endocrine Franchise, Merck & Co., Inc. “This approach is consistent with our leadership strategy of developing respiratory medicines that address unmet medical needs and deliver value to patients, physicians and payers.”

About MicroDose DPI

The MicroDose DPI is among a number of key proprietary drug delivery platforms developed by MicroDose. By employing piezo electronics, the MicroDose DPI has the potential to deliver enhanced performance, versus other inhalers, for efficient and reproducible delivery independent of patient coordination, inhalation rate and posture. MicroDose believes that the flexibility of the inhaler makes it a true platform technology, able to support a broad pipeline of products across the spectrum of patient populations and therapeutic categories.

About MicroDose Technologies MicroDose Technologies, Inc., based in Monmouth Junction, New Jersey, is a leading privately-held drug delivery systems company, developing advanced pulmonary, fixed-dose-combination oral dosage, and other technologies for the pharmaceutical and biotechnology industries.

MicroDose’s partnered programs include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the University of Pittsburgh. MicroDose is also conducting internal development programs for products employing its inhaler technology and for combination oral dosage products, employing its PolyCap(TM) technology, in the areas of diabetes, hypertension and hyperlipidemia.

For more information visit us at http://www.microdose-tech.com
Website: http://www.microdose-tech.com//

MicroDose’s partnered programs include; a multi-product development and licensing agreement with Novartis, the development of an inhaled insulin product through MicroDose’s QDose joint venture, and an inhaler for the systemic delivery of a nerve agent antidote for the US Department of Defense, in collaboration with the University of Pittsburgh. MicroDose is also conducting internal development programs for products employing its inhaler technology and for combination oral dosage products, employing its PolyCap(TM) technology, in the areas of diabetes, hypertension and hyperlipidemia.

For more information visit us at http://www.microdose-tech.com
Website: http://www.microdose-tech.com//

Issuers of news releases and not PR Newswire are solely responsible for the accuracy of the content.
Terms and conditions, including restrictions on redistribution, apply.
Copyright © 1996-2008 PR Newswire Association LLC. All Rights Reserved.
A United Business Media company